Cary J. Claiborne
Known title: Chief Executive OfficerCIK: 0001370930
Associated companies
Transaction History
| ADIL | ▲ Buy | Grant | 37,985 | $0 | 4/7/2026 | View on chart |
| ADIL | ▲ Buy | Grant | 420,000 | $0 | 5/23/2023 | View on chart |
| ADIL | ▲ Buy | Grant | 75,000 | $32K | 9/20/2022 | View on chart |
| ADIL | ▲ Buy | Grant | 25,000 | $11K | 9/19/2022 | View on chart |
| ADIL | ▲ Buy | Grant | 1,000,000 | $0 | 8/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Adial Pharmaceuticals Announces Nasdaq Inducement Grant
Adial Pharmaceuticals disclosed a new inducement grant in compliance with Nasdaq Listing Rule 5635(c)(4). This corporate action is relevant as it relates to the company's adherence to exchange listing requirements. The stock currently trades well below its 52-week high, with recent volume spikes observed alongside the announcement.
Adial Pharmaceuticals Announces Nasdaq Inducement Grant. Adial Pharmaceuticals disclosed a new inducement grant in compliance with Nasdaq Listing Rule 5635(c)(4). This corporate action is relevant as it relates to the company's adherence to exchange listing requirements. The stock currently trades well below its 52-week high, with recent volume spikes observed alongside the announcement.